Globally, India is the 4th largest producer of agrochemicals after the United States, Japan and China and has emerged as the 13th largest exporter of pesticides. It is a major hub of generic pesticides production, which leverages, among other things, the fact that branded molecules, exclusive to the producing companies, are open for larger use after the patent period of 20 years. The fact that 22 such molecules are going to come out of their patent period will substantially expand the offerings of the Indian companies to people at home and abroad alike and may help fetch extra revenue.
Agrochemical sector is deeply interested in the molecules which are going to be off-patented as it creates an opportunity for its own commercial development. Pesticide companies, especially in developing countries, wait for generic active ingredient molecules as it provides huge opportunities for generic manufacturers to provide agrochemicals at a reasonable affordable price for farmers to protect their yield from pests and disease. Moreover, generic pesticides are same in quality of patented pesticides, effectively affordable in price for Indian and global farmers, are Based on the same active substances and work in the same way in the crop as the patented pesticide but cost much less.
Both patented and generic pesticides are subject to the same approval process from the competent authority for registration, a generic pesticide is as safe and effective as the original patented pesticide
There are around 22 pesticide active ingredients which are about to get out of their IPR period in the next ten years i.e., between 2021 and 2030.
These are:
| Aminopyralid | Benzovindiflupyr | Bixafen | Chlorantraniliprole |
| Cyantraniliprole | Fenpyrazamine | Flubendiamide | Fluopicolide |
| Fluopyram | Fluxapyroxad | Isopyrazam | Penflufen |
| Penthiopyrad | Pinoxaden | Pyriofenone | Pyroxsulam |
| Mandipropamid | Saflufenacil | Sedaxane | Sulfoxaflor |
| Thiencarbazone-methyl | Valifenalate |
The demand for some of these off patented technical grade molecules in the global market is expected to increase drastically. It is expected that the market size of these products will cross over US$ 4.1 billion by 2026.
Generic molecules break the monopoly of a company who had their patent right for about 20 years without any competitor. In fact, monopoly for such a long period is dangerous as there is no control over the price of the product and it can go up as high as the manufacturer wishes. Since the last many years, it has been observed that innovators are becoming more possessive and monopolistic. The generic producers constitute about 30% of the global pesticide industry, mainly due to increase in the number of off-patented molecules and decline in new active ingredients, both of which favor generic pesticides industry which has seen a faster growth as compared to the inventor (R&D based) companies recently.
The reason is that the products like Chlorantraniliprole, Fluropyram, Fluxapyroxad, Cyantranilipore, Bixafen, Sedaxane, Fenpyrazamine and Flupicolide have a huge market. Industry players will have an opportunity, specifically in regulated markets, to choose the generic according to the demand of the market where so many products are becoming off-patent.
In India, these generic products will provide enormous growth to generic manufacturers and also to formulators who are directly or indirectly affected while the products are under IPR.
A word of caution
The increased regulatory pressure in the EU and now increasingly elsewhere is (in general) putting additional pressure on off-patent chemistry to a greater extent than patented chemistry. Companies need to consider more than just sales. Beside factors such as chemistry and regulatory, a key element for any off-patent company post 2020 is a “comprehensive” portfolio of advanced chemistry in order to compete with the “solutions focused” multinationals that can offer a “bundled” seed, trait and crop protection package.
Donald Trump’s tariffs of 50% have come into force on most US imports from India. India’s giant generic pharmaceuticals sector and its electronics and petroleum products are exempt from the tariffs. Aluminium, steel and copper remain at 25%, but job-heavy sectors such as textiles, jewellery, seafood and leather are squarely in the line of fire.
The European Chemicals Agency (ECHA) has published the updated proposal to restrict per- and polyfluoroalkyl substances (PFAS) under the EU’s chemicals regulation, REACH. The update has been prepared by the authorities from Denmark, Germany, the Netherlands, Norway and Sweden, who submitted the initial proposal in January 2023.
Most chemicals exported from the 27 member countries of the European Union into the US will be subject to a 15% tariff on top of their selling prices under an agreement signed on July 27 between the US and the European Commission.
We’re thrilled to announce a new strategic alliance between ExSyn, Exim-Indis and simABs, a leading EU-based biologics manufacturer known for its patented continuous flow technology in antibody production.
The global trade landscape is undergoing significant changes following the announcement of new reciprocal tariffs by the United States government. Recent developments indicate significant shifts in global trade dynamics, with key policy adjustments, ongoing negotiations, and evolving logistics patterns. Below is a summary of the latest developments.
In January 2025, the US FDA published a draft regulatory guidance entitled “The Considerations for Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products”.
The adoption of artificial intelligence (AI) and large language models (LLMs) is rapidly reshaping clinical research and drug development.
In the quest for increased sustainability, a lot has been made of the potential to use bio-based raw materials, captured CO2 and recycled plastics as raw materials for new chemicals. But what about using biotech processes to manufacture chemicals? Could it offer a more sustainable alternative to traditional petrochemical processing, and be more amenable to biobased raw materials?
High duties on imports from Canada, Mexico and China raise problems for international supply chains.